Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant difference between colon cancer and rectal cancer regarding the KRAS status.
|
30917791 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rapid discrimination of colon cancer cells with single base mutation in KRAS gene segment using laser tweezers Raman spectroscopy.
|
30485680 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we investigated whether combination of 5-FU and a MEK inhibitor had treatment sequence-dependent synergistic effects in KRAS or BRAF mutant colon cancer models.
|
30579838 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance.
|
30944457 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, it is demonstrated that KRAS and BRAF mutations induce anoikis resistance in colon cancer (Caco‑2) cells.
|
31545494 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The lack of mutant KRAS-induced effector activation observed in SW48 cells appears to be representative of a broad panel of colon cancer cell lines harboring mutant KRAS.
|
30785867 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
|
29127628 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium.
|
31266962 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quest for metabolic inhibitors with anti-tumour activity may constitute a novel and hopeful approach in order to handle KRAS dependent chemoresistance in colon cancer.
|
30623364 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the effects of alisertib or AURKA overexpression or knockdown in 10 upper gastrointestinal or colon cancer cell lines with KRAS mutations or amplifications using the CellTiter-Glo luminescence and clonogenic cell survival assays.
|
30342037 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, TP53 mutations were more prevalent in colon cancer with KRAS mutations than in rectal cancer (75.0% vs 28.6%, respectively, p = 0.004).
|
31729406 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study is aimed to evaluate the effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the expression of miRNAs 135b, 26b, 18a, and 155 and their target genes, including APC, PTEN, KRAS, and PU.1 in mouse azoxymethane (AOM)-induced colon cancer.
|
30311185 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NO<sub>2</sub> functionalized coumarin derivatives suppress cancer progression and facilitate apoptotic cell death in KRAS mutant colon cancer.
|
31199928 |
2019 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, we identified a KRAS codon 146 mutation (A146V), which is associated with resistance to anti-EGFR, in a cetuximab-resistant colon cancer patient with wild-type KRAS exons 2 and 12, and EGFR amplification.He received bevacizumab therapy.
|
30448735 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, Src can play a key role in apoptosis induced by the novel EGFR inhibitor MHYs, suggesting that activation of Src might prove effective in treating EGFR/wild-type KRAS colon cancer.
|
30158525 |
2018 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Together, these results identify that the HSF1-BAG3-Mcl-1 signal axis is critical for protection of mutant KRAS colon cancer cells from AUY922-induced apoptosis, with potential implications for targeting HSF1/BAG3/Mcl-1 to improve the efficacy of AUY922 in the treatment of colon cancer.
|
29068469 |
2018 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Targeting bioenergetic metabolism with mitochondria-targeted drugs to stimulate mitophagy provides an attractive approach for therapeutic intervention in KRAS WT and overactive mutant-expressing colon cancer.
|
30087121 |
2018 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identify the ERN1-JNK-JUN pathway as a novel regulator of MEK inhibitor response in KRAS mutant colon cancer.
|
30482246 |
2018 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, EGF‑ETA was just as potent in HCT116 (KRAS G13D) and SW480 (KRAS G12V) colon cancer cell lines harbouring KRAS hyperactivating mutations when compared to KRAS wild‑type HT29 colon cancer cells.
|
30226622 |
2018 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methods The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon cancer in patients who underwent SABR; patients receiving previous chemotherapy alone or in combination with bevacizumab; Karnofsky performance status >80; life expectancy >6 months; at least 6 months' follow-up after SABR; presence of KRAS mutation.
|
29737958 |
2018 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations.
|
29498789 |
2018 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the influence of BRAF and KRAS mutation status on the association between aspirin use and overall survival after colon cancer diagnosis.
|
28125730 |
2017 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, PBR increased the sensitivity of KRAS-mutated colon cancer cells to cetuximab, which indicates the potential use of PBR as a medical food against colon cancer.
|
28800074 |
2017 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In KRAS-mutant colon cancer, regulation of MAPK signaling was preserved through remaining wild-type RAS isoforms.
|
28202525 |
2017 |